Don't let the FDA warning about suicidality discourage you from prescribing an antidepressant for the child or adolescent who needs it. These recommendations provide a guide to monitoring patients for suicidal ideation and other adverse effects.
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.